Stock 600422 KPC PHARMACEUTICALS,INC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings KPC Pharmaceuticals,Inc

Equities

600422

CNE0000015P8

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 29/04/2024 am IST 		5-day change 1st Jan Change
22.87 CNY +1.51% Intraday chart for KPC Pharmaceuticals,Inc +9.48% +9.64%
19/04 KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
17/04 Kunyao Group Receives Clinical Trial Approval for FMF Drug MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
KPC PHARMACEUTICALS,INC Stock KPC Pharmaceuticals,Inc
+9.64% 2.39B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600422 Stock
  4. Ratings KPC Pharmaceuticals,Inc